Therapy for lysosomal storage disorders.

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Lysosomal storage disorders (LSDs) historically lacked specific treatments, relying on supportive care.
• Orphan drug regulations have spurred the development of novel therapies for rare LSDs.
• Enzyme replacement therapy (ERT) is now available for several LSDs, improving patient management.

Purpose of the Study:

• To review the efficacy and clinical status of current LSD treatments.
• To explore emerging therapeutic strategies for LSDs.

Main Methods:

• Review of existing literature on hematopoietic stem cell transplantation (HSCT), ERT, and substrate deprivation therapy.
• Analysis of preclinical data for novel therapies including chaperone-mediated therapy, stop-codon read-through therapy, and gene therapy.

Main Results:

• ERT has demonstrated efficacy in managing specific LSDs like Gaucher disease, Fabry disease, and Pompe disease.
• HSCT and substrate deprivation therapy are established treatment options for certain LSDs.
• Promising preclinical results are emerging for chaperone-mediated therapy, stop-codon read-through therapy, and gene therapy.

Conclusions:

• Significant therapeutic progress has been made in managing LSDs, moving beyond supportive care.
• Novel therapeutic avenues hold considerable promise for future LSD treatment strategies.